BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

WuXi Biologics Secures First Turkish GMP Certification for Three Facilities

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturin...

September 18, 2025 | News

Samsung Biologics Expands Presence in Japan with New Tokyo Office

Samsung Biologics has announced the opening of a new office in Tokyo, underscoring its long-term commitment to supporting Japan’s pharmaceutical and ...

September 09, 2025 | News

KBI Biopharma and Infinimmune Partner to Advance Manufacturing of Lead Human-First Antibody IFX-101

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotec...

September 09, 2025 | News

Andelyn Biosciences and Tern Therapeutics Partner to Advance Gene Therapy for CLN2 Batten Disease

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...

September 08, 2025 | News

China’s WuXi Biologics Secures SBTi Approval for Net-Zero Targets, Reinforcing Global Green CRDMO Leadership

Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Gre...

August 29, 2025 | News

Avance Clinical Guides 710 Emerging Biotechs Through Critical Early-Phase Milestones

Avance Clinical, a partner for biotechs providing global contract research organization services, has now guided 710 emerging biotechs through critical cli...

August 28, 2025 | News

Piramal Pharma Solutions and NewAmsterdam Pharma Expand Global OSD Manufacturing with Facilities in USA and India

Piramal Pharma Solutions, a global leader in contract development and manufacturing (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ...

August 25, 2025 | News

WuXi Biologics Posts Robust H1 2025 Results with Margin Expansion and Record Project Wins

Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded b...

August 20, 2025 | Company results

WuXi XDC Delivers 62% Revenue Growth and Record Project Momentum in H1 2025

- Revenue increased by 62.2% YoY to RMB 2,701 million - Gross profit surged by 82.2% YoY to RMB 975 million, with i...

August 19, 2025 | Company results

Bridging Real-World Evidence and AI: Unlocking Smarter, Faster Clinical Research in Asia

Having worked with pharma clients, healthcare providers, and digital platforms across the Asia-Pacific region, I’ve seen the challenges first-hand&md...

August 04, 2025 | Opinion

WuXi Biologics Begins Construction of One of the World’s Largest Modular Biologics Drug Product Facilities in Singapore

Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse ...

July 30, 2025 | News

BD Launches First Pharma-Sponsored Clinical Trial Using Libertas™ Wearable Injector for Subcutaneous Biologic Delivery

The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pr...

July 24, 2025 | News

WuXi Biologics China PFS Site Clears FDA Inspection

WuXi Biologics’ pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-qu...

July 22, 2025 | News

WuXi Biologics Launches WuXiHigh™2.0 to Enable Record-Setting High-Concentration Biologic Formulations

The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces visc...

July 01, 2025 | News

Stay Connected